Show simple item record

Authordc.contributor.authorCampanini Salinas, Javier Andrés
Authordc.contributor.authorAndrades Lagos, Juan Andrés
Authordc.contributor.authorHinojosa Torres, Nicolás Antonio
Authordc.contributor.authorMoreno Ruz, Fabián Eduardo
Authordc.contributor.authorAlarcón, Pedro
Authordc.contributor.authorGonzález Rocha, Gerardo
Authordc.contributor.authorBurbulis, Ian E.
Authordc.contributor.authorVásquez Velásquez, David
Admission datedc.date.accessioned2021-12-21T21:14:18Z
Available datedc.date.available2021-12-21T21:14:18Z
Publication datedc.date.issued2021
Cita de ítemdc.identifier.citationAntibiotics 2021, 10, 614es_ES
Identifierdc.identifier.other10.3390/antibiotics10060614
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/183342
Abstractdc.description.abstractThere is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC(R) 43300), methicillin-sensitive S. aureus (ATCC(R) 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development.es_ES
Patrocinadordc.description.sponsorshipAgencia Nacional de Investigacion y Desarrollo (ANID) de Chile through a FONDECYT Iniciacion en Investigacion Grant, Chile 11110516 FONDECYT Proyecto de Insercion, Chile 79100006 Programa de Estimulo a la Excelencia Institucional PEEI 2017, Universidad de Chile Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) CONICYT FONDECYT 1191737 CONICYT de Chile of a Beca Doctorados Nacional 21130643 21130628 Salk Institute National Institute of Allergy and Infectious Disease of the United States of America National Institutes of Health NIH 7R21AI111072es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherMDPIes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourceAntibioticses_ES
Keywordsdc.subjectMethicillin-resistant Ses_ES
Keywordsdc.subjectAureus (MRSA)es_ES
Keywordsdc.subjectDrug discoveryes_ES
Keywordsdc.subjectQuinone-antibioticses_ES
Títulodc.titleNew quinone antibiotics against methicillin-resistant S. aureuses_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorapces_ES
Indexationuchile.indexArtículo de publícación WoSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States